Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Regenxbio (RGNX) Other Non-Current Assets (2016 - 2025)

Regenxbio (RGNX) has 12 years of Other Non-Current Assets data on record, last reported at $4.6 million in Q4 2025.

  • For Q4 2025, Other Non-Current Assets rose 127.24% year-over-year to $4.6 million; the TTM value through Dec 2025 reached $4.6 million, up 127.24%, while the annual FY2025 figure was $4.6 million, 127.24% up from the prior year.
  • Other Non-Current Assets reached $4.6 million in Q4 2025 per RGNX's latest filing, up from $2.0 million in the prior quarter.
  • Across five years, Other Non-Current Assets topped out at $4.6 million in Q4 2025 and bottomed at $1.3 million in Q1 2021.
  • Average Other Non-Current Assets over 5 years is $2.1 million, with a median of $2.0 million recorded in 2021.
  • Peak YoY movement for Other Non-Current Assets: decreased 9.98% in 2024, then soared 127.24% in 2025.
  • A 5-year view of Other Non-Current Assets shows it stood at $2.0 million in 2021, then changed by 0.0% to $2.0 million in 2022, then changed by 0.0% to $2.0 million in 2023, then changed by 0.0% to $2.0 million in 2024, then surged by 127.24% to $4.6 million in 2025.
  • Per Business Quant database, its latest 3 readings for Other Non-Current Assets were $4.6 million in Q4 2025, $2.0 million in Q3 2025, and $1.9 million in Q2 2025.